Denali Therapeutics (DNLI) Shares Outstanding (2017 - 2026)

Denali Therapeutics (DNLI) has reported Shares Outstanding (Entity) for 10 consecutive years, with $158.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 9.23% year-over-year to $158.7 million; the TTM figure through Mar 2026 stood at $158.7 million (up 9.23% YoY), while the FY2025 annual figure was $156.2 million, up 8.29% from the prior year.
• Shares Outstanding (Entity) improved to $158.7 million in Q1 2026 per DNLI's latest filing, from $156.2 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $158.7 million in Q1 2026 and bottomed at $122.9 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $140.1 million across 5 years, with a median of $142.5 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 1.34% — and 2023, when it climbed 11.53%.
• Denali Therapeutics' Shares Outstanding (Entity) stood at $136.0 million in 2022, then climbed by 1.78% to $138.4 million in 2023, then rose by 4.22% to $144.2 million in 2024, then increased by 8.29% to $156.2 million in 2025, then climbed by 1.58% to $158.7 million in 2026.
• Business Quant data shows DNLI's Shares Outstanding (Entity) at $158.7 million in Q1 2026, $156.2 million in Q4 2025, and $146.6 million in Q3 2025.